Keap1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KEAP1 (Kelch-Like ECH-Associated Protein 1) is a cysteine-rich adaptor protein that serves as the primary sensor for oxidative and electrophilic stress in cells. It is the central regulator of the NRF2 (Nuclear factor erythroid 2-related factor 2) transcription factor, controlling the cellular antioxidant response and maintaining redox homeostasis. KEAP1 acts as a molecular switch that detects electrophilic molecules and oxidative damage, leading to activation of the protective NRF2 pathway.
| Property |
Value |
| Gene |
KEAP1 |
| UniProt ID |
Q14145 |
| Molecular Weight |
70 kDa |
| Length |
624 amino acids |
| Subcellular Localization |
Cytoplasm (primarily), Nucleus |
| Family |
Kelch family |
| Aliases |
INRF2, KLHL19 |
| PDB Structure |
1X2J, 2FLU, 3ZGC |
The KEAP1 protein contains multiple functional domains:
¶ BTB Domain (Residues 1-80)
- Function: Protein-protein interactions
- Key binding: CUL3/RBX1 E3 ubiquitin ligase complex
- Dimerization: Forms homodimers
- Cysteine-rich: Contains multiple reactive cysteine residues
- Sensor function: Detects oxidative/electrophilic stress
- Critical residues: C273, C288
¶ Double Glycine Repeat (DGR) Domain (Residues 315-600)
- Kelch motifs: Six kelch repeats
- NRF2 binding: Binds the NRF2 Neh2 domain
- β-propeller structure: Creates binding interface
- Nuclear localization: Contains NLS
- Protein interactions: Additional binding partners
| Cysteine |
Location |
Function |
| C151 |
BTB domain |
Primary sensor for electrophiles |
| C273 |
IVR |
Sensor for oxidative stress |
| C288 |
IVR |
Sensor region |
| C613 |
DGR domain |
NRF2 binding interface |
| C226 |
BTB domain |
Secondary sensor |
KEAP1 functions as the master regulator of cellular antioxidant response:
- NRF2 sequestration: Under basal conditions, NRF2 binds to KEAP1 Kelch domains
- Ubiquitination: CUL3/RBX1 complex ubiquitinates NRF2
- Proteasomal degradation: Polyubiquitinated NRF2 is degraded by 26S proteasome
- Homeostasis: Low NRF2 levels maintain basal transcription
- Cysteine oxidation: Oxidative/electrophilic stress modifies KEAP1 cysteines
- Conformational change: KEAP1 structure changes
- NRF2 release: NRF2 escapes ubiquitination
- Nuclear translocation: NRF2 enters nucleus
- Gene activation: Binds ARE sequences and activates detoxifying genes
- Antioxidant enzymes: SOD, CAT, GPx, HO-1
- Phase II detox enzymes: NQO1, UGT1A1, GST
- Proteasome subunits: PSMA, PSMB
- DNA repair enzymes: XPA, ERCC
- Brain: Neurons and glia, high in cortex and hippocampus
- Liver: Hepatocytes (high expression)
- Kidney: Renal tubules
- Lung: Epithelial cells
- Heart: Cardiomyocytes
- Cytoplasm: Predominant location
- F-actin: Associated with cytoskeleton
- Nucleus: Some nuclear localization under stress
The KEAP1-NRF2 pathway is critical in PD:
- Neuroprotection: NRF2 activation protects dopaminergic neurons
- Oxidative stress: Elevated ROS in substantia nigra
- KEAP1 oxidation: KEAP1 cysteines modified in PD brain
- Therapeutic potential: NRF2 activators in clinical trials
- Clinical trials: Sulforaphane, bardoxolone-methyl
KEAP1-NRF2 in AD pathogenesis:
- Aβ toxicity: KEAP1 oxidation by amyloid-β
- Tau pathology: NRF2 dysfunction in tauopathy
- Synaptic protection: NRF2 preserves synaptic function
- Neuroinflammation: Cross-talk with NF-κB pathway
- Therapeutic targeting: Direct NRF2 activators
- Motor neuron vulnerability: Impaired NRF2 pathway
- Oxidative stress: Elevated in SOD1 models
- Therapeutic potential: NRF2 activators
- Clinical evidence: Reduced NRF2 activity in ALS patients
- mHTT effects: Mutant huntingtin disrupts NRF2
- Oxidative stress: Elevated markers in HD
- Therapeutic strategy: Restore NRF2 signaling
- KEAP1 mutations: Found in lung, gallbladder, cholangiocarcinoma
- NRF2 hyperactivation: Constitutive activation in cancers
- Therapeutic resistance: Protects cancer cells from chemo
- Dual role: Both tumor suppressor and oncogene
¶ Stroke and Brain Injury
- Ischemic injury: KEAP1-NRF2 in stroke
- Neuroprotection: NRF2 activation is neuroprotective
- Therapeutic window: NRF2 activators post-stroke
| Compound |
Mechanism |
Clinical Status |
| Sulforaphane |
Covalent (C151) |
Phase II |
| Bardoxolone-methyl (CDDO-Me) |
Covalent |
Phase III (various) |
| Dimethyl fumarate (Tecfidera) |
Covalent |
FDA approved (MS) |
| Oltipraz |
Covalent |
Phase II |
| MLN1202 |
Non-covalent |
Research |
- Specificity: Off-target effects of electrophiles
- Isoform selectivity: CUL3-independent functions
- Chronic activation: Potential adverse effects
- Protein-protein interaction inhibitors: Disrupt KEAP1-NRF2 binding
- Gene therapy: AAV-NRF2 delivery
- Combination therapies: With antioxidants or anti-inflammatory agents
- Isoform-specific targeting: Understanding KEAP1 splice variants
- Cysteine selectivity: Developing selective modulators
- Biomarkers: NRF2 activity markers
- Combination approaches: Synergy with other pathways
¶ Structure and Function
¶ Domain Organization
- N-terminal region: Interacts with NRF2
- BTB domain: Dimerization, Cul3 binding
- Intervening region (IVR): Regulatory domain
- C-terminal Kelch domain: Binds NRF2 degron motif
- Open state: NRF2 can bind and be degraded
- Closed state: Covalent modification prevents NRF2 degradation
- Basal state: KEAP1 sequesters NRF2 in cytoplasm
- Ubiquitination: Cul3-RBX1 E3 ligase ubiquitinates NRF2
- Proteasomal degradation: NRF2 is degraded by 26S proteasome
- Homeostasis: Rapid turnover maintains low NRF2 levels
| Stress Type |
Sensor |
NRF2 Activation |
| Oxidative stress |
Cysteine sensors |
Direct modification |
| Electrophiles |
KEAP1 BTB domain |
Covalent adducts |
| Xenobiotics |
Multiple sensors |
Induction |
| Compound |
Mechanism |
Application |
Status |
| Sulforaphane |
Covalent KEAP1 modification |
Cancer prevention |
Clinical trials |
| Bardoxolone methyl |
Nrf2 activator |
CKD, COPD |
Clinical trials |
| Dimethyl fumarate |
KEAP1 modification |
MS, psoriasis |
FDA approved |
- Tissue specificity
- Optimal dosing
- Long-term safety
- KEAP1-/-:
- Constitutive NRF2 activation
- Enhanced protection against oxidative stress
- Developmental lethality in some backgrounds
- Resistance to carcinogenesis
- Brain-specific KEAP1 deletion: Neuroprotection in models
The study of Keap1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Cullinan SB, et al. (2004). NRF2 regulation by KEAP1: A systematic approach to understand KEAP1 function. Mol Cell Biol. PMID:15572695
[2] Kobayashi M, et al. (2006). The KEAP1-NRF2 system in cancer and aging. Antioxid Redox Signal. PMID:16705132
[3] Kensler TW, et al. (2007). Cell survival responses to environmental stresses via the KEAP1-NRF2-ARE pathway. Annu Rev Pharmacol Toxicol. PMID:17134337
[4] Hardingham GE, et al. (2015). Targeting NRF2 for neuroprotection in neurodegenerative disease. Nat Rev Neurol. PMID:26559378
[5] Cuadrado A, et al. (2019). NRF2-KEAP1 in neurodegenerative disease. Nat Rev Neurosci. PMID:31244170